Hormone Replacement Therapy (HRT)For many years, women have taken Hormone Replacement Therapy (HRT) for the purpose of reducing the symptoms of menopause. While women were led to believe taking HRT drugs (such as Prempro, Premarin, Premphase or Provera) was safe and even decreased certain health risks, studies now show that HRT can cause breast cancer and many other illnesses.
The National Institutes of Health (NIH) established the Women's Health Initiative (WHI) in 1991 to address the most common causes of death, disability and impaired quality of life in postmenopausal women. In this 15 year, multi-million dollar research project and subsequent studies, it was learned that the taking of Hormone Replacement Therapy increased the risk of breast cancer, ovarian cancer, gall bladder cancer, stroke, heart disease, blood clots, scleroderma, lupus, asthma, and other disorders and diseases. Cohen Milstein settled its first HRT case (Duetsch v. Wyeth) in July of 2002 and has several more cases scheduled for trial in New Jersey. If you have been diagnosed with any of these diseases after the time you started taking HRT, please contact us to discuss your legal rights by completing the below form and returning it to us by email lawinfo@cmht.com, fax (202-408-4699) or U.S. mail (1100 New York Ave., Ste 500W, Washington, DC 20005). You can also submit your information via email at http://www.Hormone-Replacement-Therapy-Class-Action.com. The material on this web site is for informational purposes only and does not constitute legal advice. Completion of this form or transmission of an inquiry does not contractually obligate Cohen, Milstein, Hausfeld & Toll, PLLC to represent you. We can only serve as your attorney if both you and our firm agree, in writing, that we will serve as your counsel. You should also be aware that the Statute of Limitations (the deadline imposed by law within which you may bring a lawsuit) may severely limit the time remaining for you to file any potential claims you may have. For additional information, please read the following disclaimer. |
